{"success":true,"data":{"pressRelease":{"id":"20183","rtpr_id":"nGNX7WVzq7","ticker":"ABVX","exchange":"Euronext Paris","all_tickers":["ABVX"],"title":"Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares","author":"Globe Newswire","published_at":"2026-05-05T06:00:00.603Z","article_body":"Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M\n(€38.5M) Offering of American Depositary Shares\n* Cash runway remains into Q4 2027, supporting continued funding of clinical\nprograms and pre-commercial planning activities\n* Royalty overhang materially reduced, enhancing financial flexibility to\nsupport future commercialization efforts\nPARIS, France – May 5, 2026 – 8:00 am CEST – Abivax SA\n(https://www.globenewswire.com/Tracker?data=DzuRwJkgm3QLAbxkQrVhyZhjyU2ojinOUL_jvV8GOJn13XqaPNcnBr1lLSdBHy_5V4dnSWfCBJRsNEjCQQFfJQ==)\n(Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a\nclinical-stage biotechnology company focused on developing therapeutics that\nharness the body’s natural regulatory mechanisms to modulate the immune\nresponse in patients with chronic inflammatory diseases, today announces (i)\nthe execution of a purchase agreement (the “Purchase Agreement”) for the\nroyalty certificates issued by the Company in September 2022 (the “Royalty\nCertificates”), to be partially paid in shares, and (ii) consequently, the\npricing of a $45 million offering of 403,347 ordinary shares (“Ordinary\nShares”) represented by American Depositary Shares (“ADSs”), each\nrepresenting one Ordinary Share, €0.01 nominal value per share, of the\nCompany, to the benefit of the Royalty Certificates’ holders (the\n“Holders”) at an offering price of $111.57 per ADS (the “Offering”).\n\nThe offering price of $111.57 per ADS (corresponding to €95.34 per Ordinary\nShare), based on the exchange rate of €1.00 = $1.1702 as published by the\nEuropean Central Bank on April 30, 2026, is equal to the volume-weighted\naverage trading price of the ADSs on the Nasdaq Global Market over the five\nconsecutive trading days ending on and including the trading day immediately\npreceding the pricing of the Offering (i.e., from April 27, 2026 to May 1,\n2026) and has been determined by the Board of Directors pursuant to the 26(th)\nresolution of the Company’s combined shareholders’ meeting held on June 6,\n2025 (the “General Meeting”).\n\nDidier Blondel, Chief Financial Officer of Abivax, said: “Strengthening our\nbalance sheet remains a core priority as we continue to reduce legacy\nobligations. The current market environment presents a compelling opportunity\nto proactively repurchase these royalty certificates on attractive terms,\nallowing us to simplify our capital structure and enhance long-term\nshareholder value.”\n\nPurchase of the Royalty Certificates\n\nThe Royalty Certificates have been issued to TCG Crossover Fund I, L.P., VHCP\nABVX Holdings, LLC, Deep Track Biotechnology Master Fund, Ltd., Sofinnova\nCrossover I SLP, Invus Public Equities, L.P., FPCI BioMedTech and Santé\nHoldings Srl pursuant to a decision of the Board of Directors of the Company\nheld on August 31, 2022.\n\nPursuant to the Purchase Agreement entered into between the Company and the\nHolders on May 4, 2026, the Holders have agreed to sell, and the Company has\nagreed to purchase, all of the Royalty Certificates for a purchase price equal\nto $90 million, of which $45 million shall be paid in cash on the closing\ndate, expected on or about May 7, 2026.\n\nThe Holders have agreed to grant an interest-free vendor’s loan (crédit\nvendeur) in a total amount equal to the remaining $45 million, to be\nreinvested in the Company’s securities and such loan will be set off against\nthe subscription price of the ADSs to be issued by the Company to the Holders\nin the Offering. Such set-off, and the corresponding issuance and delivery of\nthe ADSs to the Holders, is expected to occur on the closing date of the\nOffering, expected on or about May 7, 2026, at which time the vendor's loan\nwill be fully extinguished.\n\nThe Royalty Certificates repurchased by the Company will be immediately\ncancelled by the Company.\n\nType of Offering\n\nThe Ordinary Shares (in the form of ADSs) being issued in the Offering are\nbeing issued by way of a capital increase with cancellation of the\npreferential subscription rights of existing shareholders to the benefit of\nthe Holders, pursuant to the 26th resolution of the General Meeting.\n\nExpected Closing\n\nThe Offering is expected to close on or about May 7, 2026, subject to the\nsatisfaction of customary closing conditions.\n\nEstimated Proceeds from the Offering\n\nAs the subscription price of the Ordinary Shares (including in the form of\nADSs) being issued in the Offering is to be paid by way of set-off against\ncertain, liquid, and due claims against the Company, there will be no proceeds\nfrom the Offering.\n\nDilution\n\nThe 403,347 Ordinary Shares (including in the form of ADSs) to be issued in\nthe Offering will result in a dilution of approximately 0.5% of the share\ncapital of the Company (on a non-diluted basis). On an illustrative basis, a\nshareholder holding 1% of the Company’s share capital before the Offering\nwould hold a stake of 0.99% after completion of the Offering.\n\nSettlement and Delivery – Documentation\n\nThe Company’s ADSs are listed on the Nasdaq Global Market under the ticker\nsymbol “ABVX.” The Company’s Ordinary Shares are listed on the regulated\nmarket of Euronext in Paris (“Euronext”) under the symbol “ABVX.”\n\nThe Ordinary Shares issued in the Offering are expected to be admitted to\ntrading on Euronext on or about May 7, 2026. The ADSs representing the\nOrdinary Shares being issued in the Offering are expected to be admitted to\ntrading on the Nasdaq Global Market on or about May 7, 2026.\n\nThe Ordinary Shares underlying the ADSs issued in the Offering will be subject\nto an application for admission to trading on Euronext on the same trading\nline as the existing Ordinary Shares of the Company currently listed on\nEuronext, under the same ISIN code FR0012333284.\n\nAn automatic shelf registration statement on Form F-3 (including a prospectus)\nrelating to the Company’s securities was filed with the Securities and\nExchange Commission (the “SEC”) on July 23, 2025, and became effective\nupon filing. The Company intends to file with the SEC a prospectus supplement\n(and accompanying prospectus) to register any potential resale of the ADSs\n(the “Prospectus Supplement”). These documents may be obtained free of\ncharge by visiting EDGAR on the SEC’s website at www.sec.gov.\n\nThe Offering is not subject to a prospectus requiring an approval of the AMF.\n\nAccounting Treatment\n\nThe Company accounted for the repayment of the Royalty Certificates in\naccordance with applicable accounting standards, recognizing the transaction\nupon settlement and derecognizing the associated liability from its balance\nsheet. Any difference between the carrying value of the Royalty Certificates\nand the consideration paid will be recorded as a gain or loss in the\nCompany’s results of operations for quarter ended June 30, 2026.\n\nAdvisors\n\nLeerink Partners is acting as exclusive financial advisor to the Company in\nconnection with the Offering.\n\nDechert (Paris) LLP and Cooley LLP are acting as legal advisors to the Company\nin connection with the Offering.\n\nCash Position and Runway\n\nThe Company had cash, cash equivalents and short-term investments of €530.4\nmillion as of December 31, 2025, providing a projected cash runway into Q4\n2027 based on current operating assumptions.\n\nAfter the repurchase of the Royalty Certificates, the Company’s projected\ncash runway remains unchanged (into Q4 2027).\n\nRisk Factors\n\nPotential investors should carefully consider the risks described under\n“Risk Factors” in the Prospectus Supplement, including the following\nrisks:\n* Future sales of ordinary shares or ADSs by existing shareholders could\ndepress the market price of the ADSs and ordinary shares; and\n* Raising additional capital, including as a result of this offering or of\nfurther offerings to finance the clinical programs or the commercialization of\nthe Company’s drug candidates, may cause dilution to the Company’s\nshareholders, restrict its operations, or require it to relinquish rights to\nits drug candidates.\nIn addition, the Company draws attention to the risk factors related to the\nCompany and its activities described under the caption “Risk Factors” in\nthe Company’s Annual Report on Form 20-F filed with the U.S. Securities and\nExchange Commission on March 23, 2026 and in Chapter 2 of the 2026 universal\nregistration document filed with the French Financial Markets Authority\n(Autorité des Marchés Financiers – the “AMF”) under number D.26-0133\non March 23, 2026, which is available free of charge on the Company’s\nwebsite at https://ir.abivax.com/fr, as well as on the AMF’s website\nat www.amf-france.org.\n\n***\n\nAbout Abivax\n\nAbivax is a clinical-stage biotechnology company focused on developing\ntherapeutics that harness the body’s natural regulatory mechanisms to\nstabilize the immune response in patients with chronic inflammatory diseases.\nBased in France and the United States, Abivax’s lead drug candidate,\nobefazimod (ABX464), is in Phase 3 clinical trials for the treatment of\nmoderately to severely active ulcerative colitis.\n\nContacts:\n\n Abivax Investor Relations Patrick Malloy patrick.malloy@abivax.com  +1 847 987 4878  \n\nFORWARD-LOOKING STATEMENTS\n\nThis press release contains forward-looking statements, forecasts and\nestimates, including those relating to the Company’s business and financial\nobjectives. Words such as “design,” “intend,” “expect,”\n“forward,” “future,” “can,” “could,” “may,” “might,”\n“potential,” “plan,” “project,” “should,” “will” and\nvariations of such words and similar expressions are intended to identify\nforward-looking statements. These forward-looking statements include\nstatements regarding the expected closing of the Offering, the period of time\nthrough which the Company anticipates its financial resources will be adequate\nto support its operations, as well as statements concerning or implying the\ntherapeutic potential of Abivax's drug candidates, clinical development plans,\nbusiness and regulatory strategy, and anticipated future performance and other\nstatements that are not historical fact. Although Abivax’s management\nbelieves that the expectations reflected in such forward-looking statements\nare reasonable, investors are cautioned that forward-looking information and\nstatements are subject to various risks, contingencies and uncertainties, many\nof which are difficult to predict and generally beyond the control of Abivax,\nthat could cause actual results and developments to differ materially from\nthose expressed in, or implied or projected by, the forward-looking\ninformation and statements. A description of these risks, contingencies and\nuncertainties can be found in the documents filed by the Company with the AMF\npursuant to its legal obligations, including its universal registration\ndocument (Document d’Enregistrement Universel), and in the Company’s\nAnnual Report on Form 20-F filed with the U.S. Securities and Exchange\nCommission on March 23, 2026 under the caption “Risk Factors.” These\nrisks, contingencies and uncertainties include among other things, the\nuncertainties inherent in research and development, future clinical data and\nanalysis, decisions by regulatory authorities, such as the FDA or the EMA,\nregarding whether and when to approve any drug candidate, as well as their\ndecisions regarding labelling and other matters that could affect the\navailability or commercial potential of such product candidates and the\navailability of funding sufficient for the Company’s foreseeable and\nunforeseeable operating expenses and capital expenditure requirements. Special\nconsideration should be given to the potential hurdles of clinical and\npharmaceutical development including further assessment by the Company and\nregulatory agencies and IRBs/ethics committees following the assessment of\npreclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical\ndata. Furthermore, these forward-looking statements, forecasts and estimates\nare made only as of the date of this press release. Readers are cautioned not\nto place undue reliance on these forward-looking\nstatements. Abivax disclaims any obligation to update these forward-looking\nstatements, forecasts or estimates to reflect any subsequent changes that the\nCompany becomes aware of, except as required by law. Information about\npharmaceutical products (including products currently in development) that is\nincluded in this press release is not intended to constitute an advertisement.\nThis press release does not give and should not be treated as giving\ninvestment advice. It has no connection with the investment objectives,\nfinancial situation or specific needs of any recipient. It should not be\nregarded by recipients as a substitute for exercise of their own judgment. All\nopinions expressed herein are subject to change without notice.\n\nDisclaimers\n\nThis press release does not constitute an offer to sell or the solicitation of\nan offer to buy any securities of the Company, nor shall there be any sale of\nsuch securities, in any state or jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to registration or qualification\nunder the securities laws of any such state or jurisdiction.\n\nThe distribution of this press release may be subject to legal or regulatory\nrestrictions in certain jurisdictions. Any person who comes into possession of\nthis press release must inform him or herself of and comply with any such\nrestrictions.\n\nThis announcement is not a prospectus within the meaning of the Prospectus\nRegulation.\n\nIn relation to each member state of the European Economic Area (each, a\n“Relevant Member State”), an offer of the securities referred to herein is\nnot being made and will not be made to the public in that Relevant Member\nState, other than (i) to any legal entity which is a qualified investor as\ndefined in the Prospectus Regulation, (ii) to fewer than 150 natural or legal\npersons per Relevant Member State, or (iii) in any other circumstances falling\nwithin Article 1(4) of the Prospectus Regulation; provided that no such\noffer of the securities referred to herein shall require the Company to\npublish a prospectus pursuant to Article 3 of the Prospectus Regulation. For\nthe purposes of the above, the expression an “offer to the public” in any\nRelevant Member State shall have the meaning ascribed to it in Article 2(d)\nof the Prospectus Regulation.\n\nThis communication is being distributed only to, and is directed only at (a)\npersons outside the United Kingdom, (b) persons who have professional\nexperience in matters relating to investments falling within Article 19(5) of\nthe Financial Services and Markets Act 2000 (Financial Promotion) Order 2005\n(the “Order”), and (c) high net worth entities, and other persons to whom\nit may otherwise lawfully be communicated, falling within Article 49(2) of the\nOrder (all such persons together being referred to as “relevant persons”).\nAny investment or investment activity to which this communication relates is\navailable only to relevant persons and will be engaged in only with relevant\npersons. Any person who is not a relevant person should not act or rely on\nthis communication or any of its contents.\n\nSolely for the purposes of each manufacturer’s product approval process, the\ntarget market assessment in respect of the securities offered in the Offering\nhas led to the conclusion in relation to the type of clients criteria only\nthat: (i) the type of clients to whom the securities are targeted is eligible\ncounterparties and professional clients only, each as defined in Directive\n2014/65/EU, as amended (“MiFID II”); and (ii) all channels for\ndistribution of the securities offered in the Offering to eligible\ncounterparties and professional clients are appropriate. Any person\nsubsequently offering, selling or recommending the Ordinary Shares (a\n“distributor”) should take into consideration the manufacturers’ type of\nclients assessment; however, a distributor subject to MiFID II is responsible\nfor undertaking its own target market assessment in respect of the Ordinary\nShares offered in the Offering (by either adopting or refining the\nmanufacturers’ type of clients assessment) and determining appropriate\ndistribution channels.\n\nThis press release has been prepared in both French and English. In the event\nof any discrepancies between the two versions of the press release, the French\nlanguage version shall prevail.\n\nAttachment\n*     260505_Abivax_PR_Repurchase of Royalty Certificates\n(https://ml-eu.globenewswire.com/Resource/Download/4d227179-4e52-498b-86d9-dfe0fc239977)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5470cd7e-c1fe-402f-8673-925c82bbd2fb)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7WVzq7","title":"Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares","author":"Globe Newswire","ticker":"ABVX","created":"2026-05-05T06:00:00.603Z","tickers":["ABVX"],"exchange":"Euronext Paris","article_body":"Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M\n(€38.5M) Offering of American Depositary Shares\n* Cash runway remains into Q4 2027, supporting continued funding of clinical\nprograms and pre-commercial planning activities\n* Royalty overhang materially reduced, enhancing financial flexibility to\nsupport future commercialization efforts\nPARIS, France – May 5, 2026 – 8:00 am CEST – Abivax SA\n(https://www.globenewswire.com/Tracker?data=DzuRwJkgm3QLAbxkQrVhyZhjyU2ojinOUL_jvV8GOJn13XqaPNcnBr1lLSdBHy_5V4dnSWfCBJRsNEjCQQFfJQ==)\n(Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a\nclinical-stage biotechnology company focused on developing therapeutics that\nharness the body’s natural regulatory mechanisms to modulate the immune\nresponse in patients with chronic inflammatory diseases, today announces (i)\nthe execution of a purchase agreement (the “Purchase Agreement”) for the\nroyalty certificates issued by the Company in September 2022 (the “Royalty\nCertificates”), to be partially paid in shares, and (ii) consequently, the\npricing of a $45 million offering of 403,347 ordinary shares (“Ordinary\nShares”) represented by American Depositary Shares (“ADSs”), each\nrepresenting one Ordinary Share, €0.01 nominal value per share, of the\nCompany, to the benefit of the Royalty Certificates’ holders (the\n“Holders”) at an offering price of $111.57 per ADS (the “Offering”).\n\nThe offering price of $111.57 per ADS (corresponding to €95.34 per Ordinary\nShare), based on the exchange rate of €1.00 = $1.1702 as published by the\nEuropean Central Bank on April 30, 2026, is equal to the volume-weighted\naverage trading price of the ADSs on the Nasdaq Global Market over the five\nconsecutive trading days ending on and including the trading day immediately\npreceding the pricing of the Offering (i.e., from April 27, 2026 to May 1,\n2026) and has been determined by the Board of Directors pursuant to the 26(th)\nresolution of the Company’s combined shareholders’ meeting held on June 6,\n2025 (the “General Meeting”).\n\nDidier Blondel, Chief Financial Officer of Abivax, said: “Strengthening our\nbalance sheet remains a core priority as we continue to reduce legacy\nobligations. The current market environment presents a compelling opportunity\nto proactively repurchase these royalty certificates on attractive terms,\nallowing us to simplify our capital structure and enhance long-term\nshareholder value.”\n\nPurchase of the Royalty Certificates\n\nThe Royalty Certificates have been issued to TCG Crossover Fund I, L.P., VHCP\nABVX Holdings, LLC, Deep Track Biotechnology Master Fund, Ltd., Sofinnova\nCrossover I SLP, Invus Public Equities, L.P., FPCI BioMedTech and Santé\nHoldings Srl pursuant to a decision of the Board of Directors of the Company\nheld on August 31, 2022.\n\nPursuant to the Purchase Agreement entered into between the Company and the\nHolders on May 4, 2026, the Holders have agreed to sell, and the Company has\nagreed to purchase, all of the Royalty Certificates for a purchase price equal\nto $90 million, of which $45 million shall be paid in cash on the closing\ndate, expected on or about May 7, 2026.\n\nThe Holders have agreed to grant an interest-free vendor’s loan (crédit\nvendeur) in a total amount equal to the remaining $45 million, to be\nreinvested in the Company’s securities and such loan will be set off against\nthe subscription price of the ADSs to be issued by the Company to the Holders\nin the Offering. Such set-off, and the corresponding issuance and delivery of\nthe ADSs to the Holders, is expected to occur on the closing date of the\nOffering, expected on or about May 7, 2026, at which time the vendor's loan\nwill be fully extinguished.\n\nThe Royalty Certificates repurchased by the Company will be immediately\ncancelled by the Company.\n\nType of Offering\n\nThe Ordinary Shares (in the form of ADSs) being issued in the Offering are\nbeing issued by way of a capital increase with cancellation of the\npreferential subscription rights of existing shareholders to the benefit of\nthe Holders, pursuant to the 26th resolution of the General Meeting.\n\nExpected Closing\n\nThe Offering is expected to close on or about May 7, 2026, subject to the\nsatisfaction of customary closing conditions.\n\nEstimated Proceeds from the Offering\n\nAs the subscription price of the Ordinary Shares (including in the form of\nADSs) being issued in the Offering is to be paid by way of set-off against\ncertain, liquid, and due claims against the Company, there will be no proceeds\nfrom the Offering.\n\nDilution\n\nThe 403,347 Ordinary Shares (including in the form of ADSs) to be issued in\nthe Offering will result in a dilution of approximately 0.5% of the share\ncapital of the Company (on a non-diluted basis). On an illustrative basis, a\nshareholder holding 1% of the Company’s share capital before the Offering\nwould hold a stake of 0.99% after completion of the Offering.\n\nSettlement and Delivery – Documentation\n\nThe Company’s ADSs are listed on the Nasdaq Global Market under the ticker\nsymbol “ABVX.” The Company’s Ordinary Shares are listed on the regulated\nmarket of Euronext in Paris (“Euronext”) under the symbol “ABVX.”\n\nThe Ordinary Shares issued in the Offering are expected to be admitted to\ntrading on Euronext on or about May 7, 2026. The ADSs representing the\nOrdinary Shares being issued in the Offering are expected to be admitted to\ntrading on the Nasdaq Global Market on or about May 7, 2026.\n\nThe Ordinary Shares underlying the ADSs issued in the Offering will be subject\nto an application for admission to trading on Euronext on the same trading\nline as the existing Ordinary Shares of the Company currently listed on\nEuronext, under the same ISIN code FR0012333284.\n\nAn automatic shelf registration statement on Form F-3 (including a prospectus)\nrelating to the Company’s securities was filed with the Securities and\nExchange Commission (the “SEC”) on July 23, 2025, and became effective\nupon filing. The Company intends to file with the SEC a prospectus supplement\n(and accompanying prospectus) to register any potential resale of the ADSs\n(the “Prospectus Supplement”). These documents may be obtained free of\ncharge by visiting EDGAR on the SEC’s website at www.sec.gov.\n\nThe Offering is not subject to a prospectus requiring an approval of the AMF.\n\nAccounting Treatment\n\nThe Company accounted for the repayment of the Royalty Certificates in\naccordance with applicable accounting standards, recognizing the transaction\nupon settlement and derecognizing the associated liability from its balance\nsheet. Any difference between the carrying value of the Royalty Certificates\nand the consideration paid will be recorded as a gain or loss in the\nCompany’s results of operations for quarter ended June 30, 2026.\n\nAdvisors\n\nLeerink Partners is acting as exclusive financial advisor to the Company in\nconnection with the Offering.\n\nDechert (Paris) LLP and Cooley LLP are acting as legal advisors to the Company\nin connection with the Offering.\n\nCash Position and Runway\n\nThe Company had cash, cash equivalents and short-term investments of €530.4\nmillion as of December 31, 2025, providing a projected cash runway into Q4\n2027 based on current operating assumptions.\n\nAfter the repurchase of the Royalty Certificates, the Company’s projected\ncash runway remains unchanged (into Q4 2027).\n\nRisk Factors\n\nPotential investors should carefully consider the risks described under\n“Risk Factors” in the Prospectus Supplement, including the following\nrisks:\n* Future sales of ordinary shares or ADSs by existing shareholders could\ndepress the market price of the ADSs and ordinary shares; and\n* Raising additional capital, including as a result of this offering or of\nfurther offerings to finance the clinical programs or the commercialization of\nthe Company’s drug candidates, may cause dilution to the Company’s\nshareholders, restrict its operations, or require it to relinquish rights to\nits drug candidates.\nIn addition, the Company draws attention to the risk factors related to the\nCompany and its activities described under the caption “Risk Factors” in\nthe Company’s Annual Report on Form 20-F filed with the U.S. Securities and\nExchange Commission on March 23, 2026 and in Chapter 2 of the 2026 universal\nregistration document filed with the French Financial Markets Authority\n(Autorité des Marchés Financiers – the “AMF”) under number D.26-0133\non March 23, 2026, which is available free of charge on the Company’s\nwebsite at https://ir.abivax.com/fr, as well as on the AMF’s website\nat www.amf-france.org.\n\n***\n\nAbout Abivax\n\nAbivax is a clinical-stage biotechnology company focused on developing\ntherapeutics that harness the body’s natural regulatory mechanisms to\nstabilize the immune response in patients with chronic inflammatory diseases.\nBased in France and the United States, Abivax’s lead drug candidate,\nobefazimod (ABX464), is in Phase 3 clinical trials for the treatment of\nmoderately to severely active ulcerative colitis.\n\nContacts:\n\n Abivax Investor Relations Patrick Malloy patrick.malloy@abivax.com  +1 847 987 4878  \n\nFORWARD-LOOKING STATEMENTS\n\nThis press release contains forward-looking statements, forecasts and\nestimates, including those relating to the Company’s business and financial\nobjectives. Words such as “design,” “intend,” “expect,”\n“forward,” “future,” “can,” “could,” “may,” “might,”\n“potential,” “plan,” “project,” “should,” “will” and\nvariations of such words and similar expressions are intended to identify\nforward-looking statements. These forward-looking statements include\nstatements regarding the expected closing of the Offering, the period of time\nthrough which the Company anticipates its financial resources will be adequate\nto support its operations, as well as statements concerning or implying the\ntherapeutic potential of Abivax's drug candidates, clinical development plans,\nbusiness and regulatory strategy, and anticipated future performance and other\nstatements that are not historical fact. Although Abivax’s management\nbelieves that the expectations reflected in such forward-looking statements\nare reasonable, investors are cautioned that forward-looking information and\nstatements are subject to various risks, contingencies and uncertainties, many\nof which are difficult to predict and generally beyond the control of Abivax,\nthat could cause actual results and developments to differ materially from\nthose expressed in, or implied or projected by, the forward-looking\ninformation and statements. A description of these risks, contingencies and\nuncertainties can be found in the documents filed by the Company with the AMF\npursuant to its legal obligations, including its universal registration\ndocument (Document d’Enregistrement Universel), and in the Company’s\nAnnual Report on Form 20-F filed with the U.S. Securities and Exchange\nCommission on March 23, 2026 under the caption “Risk Factors.” These\nrisks, contingencies and uncertainties include among other things, the\nuncertainties inherent in research and development, future clinical data and\nanalysis, decisions by regulatory authorities, such as the FDA or the EMA,\nregarding whether and when to approve any drug candidate, as well as their\ndecisions regarding labelling and other matters that could affect the\navailability or commercial potential of such product candidates and the\navailability of funding sufficient for the Company’s foreseeable and\nunforeseeable operating expenses and capital expenditure requirements. Special\nconsideration should be given to the potential hurdles of clinical and\npharmaceutical development including further assessment by the Company and\nregulatory agencies and IRBs/ethics committees following the assessment of\npreclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical\ndata. Furthermore, these forward-looking statements, forecasts and estimates\nare made only as of the date of this press release. Readers are cautioned not\nto place undue reliance on these forward-looking\nstatements. Abivax disclaims any obligation to update these forward-looking\nstatements, forecasts or estimates to reflect any subsequent changes that the\nCompany becomes aware of, except as required by law. Information about\npharmaceutical products (including products currently in development) that is\nincluded in this press release is not intended to constitute an advertisement.\nThis press release does not give and should not be treated as giving\ninvestment advice. It has no connection with the investment objectives,\nfinancial situation or specific needs of any recipient. It should not be\nregarded by recipients as a substitute for exercise of their own judgment. All\nopinions expressed herein are subject to change without notice.\n\nDisclaimers\n\nThis press release does not constitute an offer to sell or the solicitation of\nan offer to buy any securities of the Company, nor shall there be any sale of\nsuch securities, in any state or jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to registration or qualification\nunder the securities laws of any such state or jurisdiction.\n\nThe distribution of this press release may be subject to legal or regulatory\nrestrictions in certain jurisdictions. Any person who comes into possession of\nthis press release must inform him or herself of and comply with any such\nrestrictions.\n\nThis announcement is not a prospectus within the meaning of the Prospectus\nRegulation.\n\nIn relation to each member state of the European Economic Area (each, a\n“Relevant Member State”), an offer of the securities referred to herein is\nnot being made and will not be made to the public in that Relevant Member\nState, other than (i) to any legal entity which is a qualified investor as\ndefined in the Prospectus Regulation, (ii) to fewer than 150 natural or legal\npersons per Relevant Member State, or (iii) in any other circumstances falling\nwithin Article 1(4) of the Prospectus Regulation; provided that no such\noffer of the securities referred to herein shall require the Company to\npublish a prospectus pursuant to Article 3 of the Prospectus Regulation. For\nthe purposes of the above, the expression an “offer to the public” in any\nRelevant Member State shall have the meaning ascribed to it in Article 2(d)\nof the Prospectus Regulation.\n\nThis communication is being distributed only to, and is directed only at (a)\npersons outside the United Kingdom, (b) persons who have professional\nexperience in matters relating to investments falling within Article 19(5) of\nthe Financial Services and Markets Act 2000 (Financial Promotion) Order 2005\n(the “Order”), and (c) high net worth entities, and other persons to whom\nit may otherwise lawfully be communicated, falling within Article 49(2) of the\nOrder (all such persons together being referred to as “relevant persons”).\nAny investment or investment activity to which this communication relates is\navailable only to relevant persons and will be engaged in only with relevant\npersons. Any person who is not a relevant person should not act or rely on\nthis communication or any of its contents.\n\nSolely for the purposes of each manufacturer’s product approval process, the\ntarget market assessment in respect of the securities offered in the Offering\nhas led to the conclusion in relation to the type of clients criteria only\nthat: (i) the type of clients to whom the securities are targeted is eligible\ncounterparties and professional clients only, each as defined in Directive\n2014/65/EU, as amended (“MiFID II”); and (ii) all channels for\ndistribution of the securities offered in the Offering to eligible\ncounterparties and professional clients are appropriate. Any person\nsubsequently offering, selling or recommending the Ordinary Shares (a\n“distributor”) should take into consideration the manufacturers’ type of\nclients assessment; however, a distributor subject to MiFID II is responsible\nfor undertaking its own target market assessment in respect of the Ordinary\nShares offered in the Offering (by either adopting or refining the\nmanufacturers’ type of clients assessment) and determining appropriate\ndistribution channels.\n\nThis press release has been prepared in both French and English. In the event\nof any discrepancies between the two versions of the press release, the French\nlanguage version shall prevail.\n\nAttachment\n*     260505_Abivax_PR_Repurchase of Royalty Certificates\n(https://ml-eu.globenewswire.com/Resource/Download/4d227179-4e52-498b-86d9-dfe0fc239977)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5470cd7e-c1fe-402f-8673-925c82bbd2fb)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-05T06:00:00.802472351Z","server_sent_at_ms":1777960800802},"received_at":"2026-05-05T06:00:00.864Z","source_url":null},"analysis":{"id":"14834","press_release_id":"20183","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"offering","narrative":"Abivax announced a $90 million repurchase of outstanding royalty certificates, funded by $45 million in cash and a $45 million registered direct offering to the certificate holders.\n\nThe offering consists of 403,347 American Depositary Shares priced at $111.57, equal to the five-day volume-weighted average price, resulting in approximately 0.5% dilution.\n\nManagement expects the transaction to eliminate the royalty overhang and simplify the capital structure while maintaining a cash runway into Q4 2027.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Abivax clears $90M royalty overhang with low-dilution stock swap, extending runway to Q4 2027."},"keyFigures":{"dealValueUsd":45000000,"offeringPrice":111.57,"sharesOffered":403347,"customDimensions":{"runway":"Q4 2027","cash_balance_eur":"€530.4 million","dilution_percent":0.5,"royalty_repurchase_total_usd":90000000,"cash_portion_of_repurchase_usd":45000000}},"quotedText":"Strengthening our balance sheet remains a core priority as we continue to reduce legacy obligations. The current market environment presents a compelling opportunity to proactively repurchase these royalty certificates on attractive terms, allowing us to simplify our capital structure and enhance long-term shareholder value.","namedEntities":{"people":[{"name":"Didier Blondel","role":"Chief Financial Officer"},{"name":"Patrick Malloy","role":"Investor Relations"}],"products":["obefazimod (ABX464)"],"companies":[{"name":"Abivax SA","ticker":"ABVX"},{"name":"Leerink Partners","relationship":"financial advisor"},{"name":"Dechert (Paris) LLP","relationship":"legal advisor"},{"name":"Cooley LLP","relationship":"legal advisor"},{"name":"TCG Crossover Fund I, L.P.","relationship":"royalty certificate holder"},{"name":"VHCP ABVX Holdings, LLC","relationship":"royalty certificate holder"},{"name":"Sofinnova Crossover I SLP","relationship":"royalty certificate holder"}],"dollarAmounts":[{"amount":"$90 million","context":"total purchase price of Royalty Certificates"},{"amount":"$45 million","context":"cash portion of repurchase / gross proceeds of offering"},{"amount":"$111.57","context":"offering price per ADS"},{"amount":"€530.4 million","context":"cash, cash equivalents and short-term investments as of Dec 31, 2025"}]},"materialImpact":{"score":3,"reasoning":"The company is eliminating a $90 million liability (royalty certificates) through a combination of cash and a small, market-priced equity offering. The 0.5% dilution is modest, and the transaction strengthens the balance sheet while preserving the Q4 2027 cash runway."},"tickerRelevance":{"others":[],"primary":"ABVX"},"globalImportance":18,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"balance-sheet-optimization","dilutionLevel":"low","issuerAuthored":true}},"event_type":"offering","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Abivax announced a $90 million repurchase of outstanding royalty certificates, funded by $45 million in cash and a $45 million registered direct offering to the certificate holders.\n\nThe offering consists of 403,347 American Depositary Shares priced at $111.57, equal to the five-day volume-weighted average price, resulting in approximately 0.5% dilution.\n\nManagement expects the transaction to eliminate the royalty overhang and simplify the capital structure while maintaining a cash runway into Q4 2027.","key_figures":{"dealValueUsd":45000000,"offeringPrice":111.57,"sharesOffered":403347,"customDimensions":{"runway":"Q4 2027","cash_balance_eur":"€530.4 million","dilution_percent":0.5,"royalty_repurchase_total_usd":90000000,"cash_portion_of_repurchase_usd":45000000}},"named_entities":{"people":[{"name":"Didier Blondel","role":"Chief Financial Officer"},{"name":"Patrick Malloy","role":"Investor Relations"}],"products":["obefazimod (ABX464)"],"companies":[{"name":"Abivax SA","ticker":"ABVX"},{"name":"Leerink Partners","relationship":"financial advisor"},{"name":"Dechert (Paris) LLP","relationship":"legal advisor"},{"name":"Cooley LLP","relationship":"legal advisor"},{"name":"TCG Crossover Fund I, L.P.","relationship":"royalty certificate holder"},{"name":"VHCP ABVX Holdings, LLC","relationship":"royalty certificate holder"},{"name":"Sofinnova Crossover I SLP","relationship":"royalty certificate holder"}],"dollarAmounts":[{"amount":"$90 million","context":"total purchase price of Royalty Certificates"},{"amount":"$45 million","context":"cash portion of repurchase / gross proceeds of offering"},{"amount":"$111.57","context":"offering price per ADS"},{"amount":"€530.4 million","context":"cash, cash equivalents and short-term investments as of Dec 31, 2025"}]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-05T06:10:11.844Z","global_importance":18,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"balance-sheet-optimization","dilutionLevel":"low","issuerAuthored":true}},"durationMs":113040,"modelName":"glm-4.7"}}